Viatris Beats Q2 Estimates, Lifts 2026 Profit Outlook on Branded Drug Strength
VTRS has more than doubled off its 52-week low of $8.735.
Summary
Viatris delivered a strong Q2, with revenue of $3.76B beating the $3.66B consensus and adjusted EPS of $0.69 topping estimates by 9 cents. Branded drugs drove the beat, with the unit's revenue up 6% to $2.42B, while Greater China sales surged 21% to $713.8M. Management raised full-year adjusted EPS guidance to $2.45-$2.59 from $2.33-$2.47 and nudged the revenue range higher at the low end. The company also disclosed a $100M-$150M H2 revenue headwind from a fire at its Nashik plant, but the guidance raise suggests confidence in offsetting that impact. Separately, Viatris sold global rights to dry-eye treatment Tyrvaya to Harrow for $30M upfront plus $70M in milestones, a modest divestiture that sharpens portfolio focus. Shares rose nearly 2% premarket, reflecting the earnings beat and improved outlook.
At the time of this announcement, VTRS was trading at $17.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.7B. The 52-week trading range was $8.74 to $18.07. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.